223 related articles for article (PubMed ID: 32430679)
1. Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
van Steenhoven JEC; den Dekker BM; Kuijer A; van Diest PJ; Nieboer P; Zuetenhorst JM; Imholz ALT; Siesling S; van Dalen T
Breast Cancer Res Treat; 2020 Jul; 182(1):107-115. PubMed ID: 32430679
[TBL] [Abstract][Full Text] [Related]
2. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
[TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
[TBL] [Abstract][Full Text] [Related]
4. The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
MacDonald KV; Bombard Y; Deal K; Trudeau M; Leighl N; Marshall DA
Eur J Cancer; 2016 Jul; 61():85-93. PubMed ID: 27155447
[TBL] [Abstract][Full Text] [Related]
5. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
6. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
7. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
[TBL] [Abstract][Full Text] [Related]
8. The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer.
van Steenhoven JEC; Kuijer A; Schreuder K; Elias SG; van Diest PJ; van der Wall E; Siesling S; van Dalen T
Ann Surg Oncol; 2019 Oct; 26(11):3495-3501. PubMed ID: 31209664
[TBL] [Abstract][Full Text] [Related]
9. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
Fallowfield L; Matthews L; May S; Jenkins V; Bloomfield D
Psychooncology; 2018 Apr; 27(4):1264-1269. PubMed ID: 29448311
[TBL] [Abstract][Full Text] [Related]
10. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
11. Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.
Kuijer A; Straver M; den Dekker B; van Bommel ACM; Elias SG; Smorenburg CH; Wesseling J; Linn SC; Rutgers EJT; Siesling S; van Dalen T
J Clin Oncol; 2017 Aug; 35(24):2814-2819. PubMed ID: 28813638
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of the Japanese version of the Decisional Conflict Scale to investigate the value of pharmacists' information: a before and after study.
Kawaguchi T; Azuma K; Yamaguchi T; Soeda H; Sekine Y; Koinuma M; Takeuchi H; Akashi T; Unezaki S
BMC Med Inform Decis Mak; 2013 Apr; 13():50. PubMed ID: 23594514
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2- Breast Cancer.
van Steenhoven JEC; van Dalen T
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):800-801. PubMed ID: 31650304
[No Abstract] [Full Text] [Related]
14. Does Patient Preference Measurement in Decision Aids Improve Decisional Conflict? A Randomized Trial in Men with Prostate Cancer.
Shirk JD; Crespi CM; Saucedo JD; Lambrechts S; Dahan E; Kaplan R; Saigal C
Patient; 2017 Dec; 10(6):785-798. PubMed ID: 28623628
[TBL] [Abstract][Full Text] [Related]
15. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Eiermann W; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Schneeweiss A; Markmann S; Eggemann H; Hilfrich J; Jackisch C; Witzel I; Eidtmann H; Bachinger A; Hell S; Blohmer J
Ann Oncol; 2013 Mar; 24(3):618-24. PubMed ID: 23136233
[TBL] [Abstract][Full Text] [Related]
16. Effect of a decision aid with patient narratives in reducing decisional conflict in choice for surgery among early-stage breast cancer patients: A three-arm randomized controlled trial.
Osaka W; Nakayama K
Patient Educ Couns; 2017 Mar; 100(3):550-562. PubMed ID: 28277290
[TBL] [Abstract][Full Text] [Related]
17. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer.
Yamauchi H; Nakagawa C; Takei H; Chao C; Yoshizawa C; Yagata H; Yoshida A; Hayashi N; Hell S; Nakamura S
Clin Breast Cancer; 2014 Jun; 14(3):191-7. PubMed ID: 24321102
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results.
Rini C; O'Neill SC; Valdimarsdottir H; Goldsmith RE; Jandorf L; Brown K; DeMarco TA; Peshkin BN; Schwartz MD
Health Psychol; 2009 Sep; 28(5):569-578. PubMed ID: 19751083
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
